The impact of drug metabolism gene polymorphisms on therapeutic response and survival in diffuse large B-cell lymphoma patients

Ildikó Pál, A. Illés, L. Gergely, Tibor Pál, Zita Radnay, Z. Szekanecz, E. Zilahi, László Váróczy

Research output: Contribution to journalArticle

Abstract

Background: Diffuse large B-cell lymphoma (DLBCL) accounts for 30% of all non-Hodgkin lymphomas (NHL) and 80% of agressive lymphomas. Besides the traditional International Prognostic Index (IPI), some other factors may also influence the prognosis of DLBCL patients. Objectives: To study how the genetic polymorphisms in the metabolic pathway influence the event-free and overall survivals and therapeutic responses in DLBCL. Methods: The study was comprised of 51 patients (32 men, 19 women). The average age was 53.1 years. DLBCL was diagnosed between 2011 and 2016 and the average follow-up time was 3.78 years. These patients received 1–8 cycles (an average of 6.2 cycles) of rituximab, cyclophosphamide, doxorubicin, vincristin, prednisolon (R-CHOP) immunochemotherapy. Real-time polymerase chain reaction was used to determine the genetic polymorphisms of CYP2E1, GSTP1, NAT1, and NAT2 genes. Results: Our results showed that the polymorphisms of CYP2E1, GSTP1, and NAT1 genes did not influence the prognosis of DLBCL patients significantly. In terms of the NAT2 gene, GG homozygous patients showed slightly better therapeutic response and survival results compared to those bearing an A allele; however, the differences were not statistically significant. Conclusions: Our results could not confirm that genetic polymorphism in metabolic pathways has any predictive role in DLBCL.

Original languageEnglish
Pages (from-to)217-221
Number of pages5
JournalIsrael Medical Association Journal
Volume20
Issue number4
Publication statusPublished - Apr 1 2018

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Survival
Genetic Polymorphisms
Pharmaceutical Preparations
Genes
Cytochrome P-450 CYP2E1
Metabolic Networks and Pathways
Therapeutics
Prednisolone
Non-Hodgkin's Lymphoma
Doxorubicin
Cyclophosphamide
Disease-Free Survival
Real-Time Polymerase Chain Reaction
Lymphoma
Alleles

Keywords

  • Diffuse large B-cell lymphoma (DLBCL)
  • Event-free survival
  • Genetic polymorphism
  • Non-Hodgkin lymphoma (NHL)
  • Therapeutic efficacy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The impact of drug metabolism gene polymorphisms on therapeutic response and survival in diffuse large B-cell lymphoma patients. / Pál, Ildikó; Illés, A.; Gergely, L.; Pál, Tibor; Radnay, Zita; Szekanecz, Z.; Zilahi, E.; Váróczy, László.

In: Israel Medical Association Journal, Vol. 20, No. 4, 01.04.2018, p. 217-221.

Research output: Contribution to journalArticle

@article{27035d9d00114897837e5aeb5d013b0f,
title = "The impact of drug metabolism gene polymorphisms on therapeutic response and survival in diffuse large B-cell lymphoma patients",
abstract = "Background: Diffuse large B-cell lymphoma (DLBCL) accounts for 30{\%} of all non-Hodgkin lymphomas (NHL) and 80{\%} of agressive lymphomas. Besides the traditional International Prognostic Index (IPI), some other factors may also influence the prognosis of DLBCL patients. Objectives: To study how the genetic polymorphisms in the metabolic pathway influence the event-free and overall survivals and therapeutic responses in DLBCL. Methods: The study was comprised of 51 patients (32 men, 19 women). The average age was 53.1 years. DLBCL was diagnosed between 2011 and 2016 and the average follow-up time was 3.78 years. These patients received 1–8 cycles (an average of 6.2 cycles) of rituximab, cyclophosphamide, doxorubicin, vincristin, prednisolon (R-CHOP) immunochemotherapy. Real-time polymerase chain reaction was used to determine the genetic polymorphisms of CYP2E1, GSTP1, NAT1, and NAT2 genes. Results: Our results showed that the polymorphisms of CYP2E1, GSTP1, and NAT1 genes did not influence the prognosis of DLBCL patients significantly. In terms of the NAT2 gene, GG homozygous patients showed slightly better therapeutic response and survival results compared to those bearing an A allele; however, the differences were not statistically significant. Conclusions: Our results could not confirm that genetic polymorphism in metabolic pathways has any predictive role in DLBCL.",
keywords = "Diffuse large B-cell lymphoma (DLBCL), Event-free survival, Genetic polymorphism, Non-Hodgkin lymphoma (NHL), Therapeutic efficacy",
author = "Ildik{\'o} P{\'a}l and A. Ill{\'e}s and L. Gergely and Tibor P{\'a}l and Zita Radnay and Z. Szekanecz and E. Zilahi and L{\'a}szl{\'o} V{\'a}r{\'o}czy",
year = "2018",
month = "4",
day = "1",
language = "English",
volume = "20",
pages = "217--221",
journal = "Israel Medical Association Journal",
issn = "1565-1088",
publisher = "Israel Medical Association",
number = "4",

}

TY - JOUR

T1 - The impact of drug metabolism gene polymorphisms on therapeutic response and survival in diffuse large B-cell lymphoma patients

AU - Pál, Ildikó

AU - Illés, A.

AU - Gergely, L.

AU - Pál, Tibor

AU - Radnay, Zita

AU - Szekanecz, Z.

AU - Zilahi, E.

AU - Váróczy, László

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: Diffuse large B-cell lymphoma (DLBCL) accounts for 30% of all non-Hodgkin lymphomas (NHL) and 80% of agressive lymphomas. Besides the traditional International Prognostic Index (IPI), some other factors may also influence the prognosis of DLBCL patients. Objectives: To study how the genetic polymorphisms in the metabolic pathway influence the event-free and overall survivals and therapeutic responses in DLBCL. Methods: The study was comprised of 51 patients (32 men, 19 women). The average age was 53.1 years. DLBCL was diagnosed between 2011 and 2016 and the average follow-up time was 3.78 years. These patients received 1–8 cycles (an average of 6.2 cycles) of rituximab, cyclophosphamide, doxorubicin, vincristin, prednisolon (R-CHOP) immunochemotherapy. Real-time polymerase chain reaction was used to determine the genetic polymorphisms of CYP2E1, GSTP1, NAT1, and NAT2 genes. Results: Our results showed that the polymorphisms of CYP2E1, GSTP1, and NAT1 genes did not influence the prognosis of DLBCL patients significantly. In terms of the NAT2 gene, GG homozygous patients showed slightly better therapeutic response and survival results compared to those bearing an A allele; however, the differences were not statistically significant. Conclusions: Our results could not confirm that genetic polymorphism in metabolic pathways has any predictive role in DLBCL.

AB - Background: Diffuse large B-cell lymphoma (DLBCL) accounts for 30% of all non-Hodgkin lymphomas (NHL) and 80% of agressive lymphomas. Besides the traditional International Prognostic Index (IPI), some other factors may also influence the prognosis of DLBCL patients. Objectives: To study how the genetic polymorphisms in the metabolic pathway influence the event-free and overall survivals and therapeutic responses in DLBCL. Methods: The study was comprised of 51 patients (32 men, 19 women). The average age was 53.1 years. DLBCL was diagnosed between 2011 and 2016 and the average follow-up time was 3.78 years. These patients received 1–8 cycles (an average of 6.2 cycles) of rituximab, cyclophosphamide, doxorubicin, vincristin, prednisolon (R-CHOP) immunochemotherapy. Real-time polymerase chain reaction was used to determine the genetic polymorphisms of CYP2E1, GSTP1, NAT1, and NAT2 genes. Results: Our results showed that the polymorphisms of CYP2E1, GSTP1, and NAT1 genes did not influence the prognosis of DLBCL patients significantly. In terms of the NAT2 gene, GG homozygous patients showed slightly better therapeutic response and survival results compared to those bearing an A allele; however, the differences were not statistically significant. Conclusions: Our results could not confirm that genetic polymorphism in metabolic pathways has any predictive role in DLBCL.

KW - Diffuse large B-cell lymphoma (DLBCL)

KW - Event-free survival

KW - Genetic polymorphism

KW - Non-Hodgkin lymphoma (NHL)

KW - Therapeutic efficacy

UR - http://www.scopus.com/inward/record.url?scp=85045523914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045523914&partnerID=8YFLogxK

M3 - Article

C2 - 29629728

AN - SCOPUS:85045523914

VL - 20

SP - 217

EP - 221

JO - Israel Medical Association Journal

JF - Israel Medical Association Journal

SN - 1565-1088

IS - 4

ER -